Study data show that one-third of the
IDgenetix-guided medication recommendations were due to drug-drug
interactions and lifestyle factors, demonstrating the value of this
additional information in guiding selection of neuropsychiatric
medications for older adults in cohort of patients 65 and older,
with majority being on five or more medications at the time of
testing
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced new data highlighting the value of its IDgenetix
pharmacogenomic (PGx) test in guiding medication recommendations
for patients with mental health conditions who are 65 and older.
The data will be shared via a poster presentation at the 2024
American Association for Geriatric Psychiatry (AAGP) Annual
Meeting, taking place March 15-18 in Atlanta.
“Pharmacogenomics has been increasingly used to identify genetic
variations associated with drug response; however, its potential in
older adults who are more likely to be on multiple medications and
experience adverse drug events has not been fully explored,” said
Robert Cook, Ph.D., senior vice president of research and
development at Castle Biosciences. “This study found that, despite
all patients carrying potentially clinically significant genetic
variants, one-third of medication recommendations were due to
drug-drug interactions and lifestyle factors provided on the
IDgenetix report. This is especially important as real-world
evidence shows that polypharmacy, taking five or more prescription
medications, occurs in more than half of elderly patients.1”
Poster Title: Pharmacogenomic Characteristics and
IDgenetix-Guided Medication Management for Older Adults with
Depression and Anxiety
Presenting Author: Raymond A. Lorenz, Pharm.D., BCPP, Castle
Biosciences, Inc.
Date and Time: Saturday, March 16, from 5-7 p.m. Eastern
Time
Location: Grand Ballroom, Hanover Hall and Embassy Hall
Exhibition Level at the Hyatt Regency Atlanta
IDgenetix is an advanced 3-in-1 PGx test that incorporates
genetic information, drug-drug interactions and lifestyle factors
to produce a report that can help clinicians select optimal
medications for their patients with depression, anxiety and other
neuropsychiatric illnesses. The study analyzed gender, age and
diagnosis, including attention-deficit/hyperactivity disorder,
anxiety, bipolar disorder, depression, obsessive-compulsive
personality disorder, pain, post-traumatic stress disorder and
schizophrenia, from a sample of IDgenetix reports for patients 65
and older (n=737). The most common psychiatric diagnoses for which
IDgenetix was ordered included depression and anxiety.
Additionally, 58% of the patients in the study were on five or more
medications, with an average of seven, at the time of testing.
All patients in the study had genetic polymorphisms that could
impact medication selection in at least three of the 15 genes on
the IDgenetix report. While drug-gene interactions accounted for
66% of all medication recommendations, drug-drug interactions and
lifestyle factors accounted for 34% (27% and 7%, respectively),
demonstrating the value of the IDgenetix 3-in-1 test in providing
tailored guidance to help clinicians select the optimal medications
for their patients.
About IDgenetix
IDgenetix is a pharmacogenomic (PGx) test for depression,
anxiety and other mental health conditions designed to analyze a
patient’s genetic make-up to guide timely and evidence-based
decisions on the optimal drug for each patient. IDgenetix is
designed to provide important genetic information to clinicians to
help guide personalized treatment plans for their patients, with
the potential to help patients achieve a faster therapeutic
response and improve their chances of remission by identifying
appropriate medications more efficiently than the standard of care
trial-and-error approach. IDgenetix provides drug-drug and
drug-gene interactions and is supported by a published,
peer-reviewed randomized controlled trial that demonstrated
clinical utility over the standard of care when physicians used
IDgenetix prior to prescribing a medication. IDgenetix is currently
reimbursed by Medicare for the following eight mental health
conditions: major depressive disorder, schizophrenia, bipolar
disorder, anxiety disorders, panic disorder, obsessive-compulsive
personality disorder, post-traumatic stress disorder and attention
deficit hyperactivity disorder.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
Barrett’s esophagus, mental health conditions and uveal melanoma.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to help guide systemic therapy
selection for patients with moderate-to-severe atopic dermatitis,
psoriasis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM,
DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle
Biosciences, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the “safe harbor” created by those
sections. These forward-looking statements include, but are not
limited to, statements concerning: the potential of
pharmacogenomics to affect medication recommendations for older
adults; and the value of the IDgenetix 3-in-1 test in providing
tailored guidance to help clinicians select the optimal medications
for their patients. The words “believe,” “can” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. We may not actually achieve the plans,
intentions or expectations disclosed in our forward-looking
statements, and you should not place undue reliance on our
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements that we make. These forward-looking
statements involve risks and uncertainties that could cause our
actual results to differ materially from those in the
forward-looking statements, including, without limitation:
subsequent study or trial results and findings may contradict
earlier study or trial results and findings or may not support the
results obtained in these studies, including with respect to the
discussion of our tests in this press release; actual application
of our tests may not provide the aforementioned benefits to
patients; and the risks set forth under the heading “Risk Factors”
in our Annual Report on Form 10-K for the year ended December 31,
2023, and in our other filings with the SEC. The forward-looking
statements are applicable only as of the date on which they are
made, and we do not assume any obligation to update any
forward-looking statements, except as may be required by law.
1. Wang X, Liu K, Shirai K, et al. Prevalence and trends of
polypharmacy in U.S. adults, 1999–2018. Glob Health Res Policy.
2023;8(25). https://doi.org/10.1186/s41256-023-00311-4
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240315064353/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Apr 2024 to May 2024
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From May 2023 to May 2024